# A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke

> **NCT05515393** · PHASE2 · UNKNOWN · sponsor: **Shijiazhuang Yiling Pharmaceutical Co. Ltd** · enrollment: 420 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** XY03-EA
- **DRUG:** XY03-EA Placebo

## Key facts

- **NCT ID:** NCT05515393
- **Lead sponsor:** Shijiazhuang Yiling Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-24
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05515393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05515393, "A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05515393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*